Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.